Revance Therapeutics Inc.

About Revance Therapeutics Inc.

Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.

Products & Services

DAXXIFY (Peptide-Powered Neuromodulator):Indicated for temporary improvement of moderate to severe glabellar lines and treatment of cervical dystonia in adults.

Teoxane RHA Collection (Hyaluronic Acid Filler):Innovative hyaluronic acid filler now with Mepivacaine for aesthetic treatments.

SkinPen (#1 Microneedling Brand in the U.S.):A leading microneedling device for skin treatment, owned by Crown Aesthetics, a Revance company.

BIOJUVE (Living Microbe Technology):Clinically proven skincare technology, owned by Crown Aesthetics, a Revance company.

PanOxyl (The Acne Authority™):A consumer skincare product for acne treatment, owned by Crown Laboratories, a Revance company.

StriVectin (The Science Behind Great Skin™):A consumer skincare brand focused on effective skin solutions, owned by Crown Laboratories.

Blue Lizard Sunscreen (#1 Selling Mineral Sunscreen Brand):A leading mineral sunscreen brand, owned by Crown Laboratories.

Sarna Lotion (#1 Dermatologist Recommended Topical Anti-Itch Brand):A topical anti-itch solution, owned by Crown Laboratories.

Desenex (Athlete's Foot Cream and Powder):Prescription-strength products for athlete's foot, owned by Crown Laboratories.

Keri Lotion (Whole Body Moisture Therapy):A moisturizing lotion for dry skin relief, owned by Crown Laboratories.

Specialties

Innovative Aesthetics Market-Leading Skincare Neuromodulators Hyaluronic Acid Fillers Microneedling Living Microbe Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 100000000 MR: - FA: 100.0 million FAN: 100000000	D: 2024-03-04 FD: 2024-03-04	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-03-04 FD: 2024-03-04	1 investors

Public Offering of Common Stock Latest

2024-03-04

$100.0M

1 investor (Pro only)

Public Offering 2024-03-04

$100.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nadeem Moiz

Chief Executive Officer

S

Scott Leffler

Chief Financial Officer

K

Kira Schwartz

Chief Legal Officer

N

Nick Crowe

Chief Operating Officer

M

Matt Argano, Ph.D.

Chief Human Resources Officer

M

Michael McKenna

Executive Vice President And Chief Sales Officer, Aesthetics

View 17 more team members with Pro

Unlock Full Team Directory

Recent News